Skip to main content
Top
Published in: Sleep and Breathing 5/2023

15-12-2022 | Sleep Apnea | Sleep Breathing Physiology and Disorders • Short Communication

Potential health risks of sound abatement material in positive airway pressure devices for sleep breathing disorders: a summary of studies to date

Authors: Yuxin Wang, Yi Xiao

Published in: Sleep and Breathing | Issue 5/2023

Login to get access

Abstract

Purpose

The potential carcinogenic and airway irritation risks of polyester-based polyurethane (PE-PUR) contained in sound-absorbing foam in positive airway pressure (PAP) devices have raised many concerns. We summarize the currently available studies to assess the potential health risks of PE-PUR.

Methods

We searched Pubmed and Web of Science for studies on the safety of PAP devices containing PE-PUF and performed a systematic analysis of the cancer risk.

Results

PE-PUR did not increase the cancer risk (OR: 1.08, 95% CI: 0.99–1.17, I2 = 0%). Patients in the group of PE-PUR devices had increased airway irritation, and they had higher rates of using short-acting beta-agonists and oral corticosteroids (SABA: 9.4% vs. 8.8%, p = 0.047; OCS: 19.7% vs. 17.3%, p < 0.001).

Conclusion

The application of PE-PUF can increase airway irritation, but there is no evidence for its potential carcinogenicity.
Literature
3.
go back to reference Kendzerska T, Leung RS, Boulos MI, Mcisaac DI, Murray BJ, Bryson GL, Talarico R, Malhotra A, Gershon AS, Mackenzie C et al (2021) An association between positive airway pressure device manufacturer and incident cancer? A Secondary Data Analysis. Am J Respir Crit Care Med 204(12):1484–1488CrossRefPubMedPubMedCentral Kendzerska T, Leung RS, Boulos MI, Mcisaac DI, Murray BJ, Bryson GL, Talarico R, Malhotra A, Gershon AS, Mackenzie C et al (2021) An association between positive airway pressure device manufacturer and incident cancer? A Secondary Data Analysis. Am J Respir Crit Care Med 204(12):1484–1488CrossRefPubMedPubMedCentral
4.
go back to reference Palm A, Grote L, Ekström M, Ljunggren M (2022) Health risks related to polyurethane foam degradation in CPAP devices used for sleep apnoea treatment. Eur Respir J 59(5):2200237CrossRefPubMedPubMedCentral Palm A, Grote L, Ekström M, Ljunggren M (2022) Health risks related to polyurethane foam degradation in CPAP devices used for sleep apnoea treatment. Eur Respir J 59(5):2200237CrossRefPubMedPubMedCentral
5.
go back to reference Justeau G, Gervès-Pinquié C, Jouvenot M, Pigeanne T, Launois S, Leclair-Visonneau L, Masson P, Bizieux-Thaminy A, Bailly S, Meslier N et al (2022) Cancer risk in adherent users of polyurethane foam-containing CPAP devices for sleep apnoea. Eur Respir J 60(1):2200551CrossRefPubMedPubMedCentral Justeau G, Gervès-Pinquié C, Jouvenot M, Pigeanne T, Launois S, Leclair-Visonneau L, Masson P, Bizieux-Thaminy A, Bailly S, Meslier N et al (2022) Cancer risk in adherent users of polyurethane foam-containing CPAP devices for sleep apnoea. Eur Respir J 60(1):2200551CrossRefPubMedPubMedCentral
6.
go back to reference Brauer PR, Bryson PC, Wu SS, Gau VL, Lamarre ED, Kominsky AH (2022) Cancer risk associated with continuous positive airway pressure: a national study. Laryngoscope 132(11):2270–2274CrossRefPubMedPubMedCentral Brauer PR, Bryson PC, Wu SS, Gau VL, Lamarre ED, Kominsky AH (2022) Cancer risk associated with continuous positive airway pressure: a national study. Laryngoscope 132(11):2270–2274CrossRefPubMedPubMedCentral
Metadata
Title
Potential health risks of sound abatement material in positive airway pressure devices for sleep breathing disorders: a summary of studies to date
Authors
Yuxin Wang
Yi Xiao
Publication date
15-12-2022
Publisher
Springer International Publishing
Keyword
Sleep Apnea
Published in
Sleep and Breathing / Issue 5/2023
Print ISSN: 1520-9512
Electronic ISSN: 1522-1709
DOI
https://doi.org/10.1007/s11325-022-02763-3

Other articles of this Issue 5/2023

Sleep and Breathing 5/2023 Go to the issue

Sleep Breathing Physiology and Disorders • Original Article

Sleep and obstructive sleep apnea in women with infertility

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.